Oncolytics Biotech Value Stock - Dividend - Research Selection
Oncolytics Biotech
ISIN: CA6823108759, WKN: A2JMW5
Market price: 3,69 CAD
Oncolytics Biotech Fundamental data and company key figures of the share
| Annual reports in CAD | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Key figures | 10-03-2021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net operating cash flow | -22.068.400 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Capital Expenditures | -29.305 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | -22.097.704 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
| Total Equity | 24.753.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Liabilities & Shareholders equity | 34.345.600 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
| Net income | -22.505.100 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Eps (diluted) | -0,560 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 46.167.000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Net sales/revenue | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
| Description | Data |
|---|---|
| Symbol | ONC.TO |
| Market Capitalization | 130.291.568,00 USD |
| Country | |
| Indices | NO INDEX |
| Sectors | |
| Raw Data Source | IFRS in Millionen CAD |
| Stock Split | 2018-05-25,105.0000/1000.0000 |
| Internet | www.oncolyticsbiotech.com |
Description of the company
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.